Leukine

(sargramostim)

Phase 3Protein / enzyme

Sargramostim is used to help boost white blood cell production in cancer patients undergoing chemotherapy or bone marrow transplants, helping their immune system recover and fight infections.[1] Leukine is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]

Leukine is one of 217 biologic programs targeting Aplastic Anemia. It is currently in Phase 3.

Indications

306

Total Trials

Active Trials

216

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

NeuroblastomaCompleted

Multiple MyelomaCompleted

Alzheimer's DiseaseRecruiting

High-Risk NeuroblastomaCompleted

GanglioneuroblastomaRecruiting

Anatomic Stage IV Breast Cancer AJCC V8Recruiting

Anatomic Stage IB Breast Cancer AJCC V8Active, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Recruiting

Lung Non-Small Cell CarcinomaRecruiting

Aplastic AnemiaPreclinical

Active, not recruiting

NeuroblastomaPhase 3

Completed

Multiple MyelomaPhase 2

Completed

Alzheimer's DiseasePhase 2

Recruiting

High-Risk NeuroblastomaPhase 3

Completed

GanglioneuroblastomaPhase 3

Recruiting

Anatomic Stage IV Breast Cancer AJCC V8Phase 2

Recruiting

Anatomic Stage IB Breast Cancer AJCC V8Phase 2

Active, not recruiting

Anatomic Stage III Breast Cancer AJCC V8Preclinical

Recruiting

Lung Non-Small Cell CarcinomaPhase 2

Recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

43 2

Venclexta

AbbVie

Phase 3

17 3

Keytruda

Merck & Co.

Phase 3

17 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 5

Leukine

Sanofi

Phase 3

11 6

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 7

Etentamig

AbbVie

Phase 3

8 8

Adriamycin

HHRYZ Biotech Co.

Phase 3

4 9

CM336

KKeymed Biosciences Co.Ltd

Phase 3

2 10

Cevostamab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Neuroblastoma

NCT04385277

Clinical

Trials by Indication[1]

Lymphoma20 trials

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00621036

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004198

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed·MMontefiore Medical Center·Phase 2·NCT00002461·35 enrolled

Show 17 more trials

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated·—·Phase 1·NCT00003567·8 enrolled

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000658·250 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00389818·43 enrolled

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Completed·GGenitope Corporation·Phase 2·NCT00071955

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

Terminated·FFavrille·Phase 2·NCT00104819·238 enrolled

Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT00004162·48 enrolled

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Unknown status·GGenitope Corporation·Phase 3·NCT00017290

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Unknown status·FFavrille·Phase 2·NCT00258336·56 enrolled

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Terminated·FFavrille·Phase 3·NCT00089115

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Withdrawn·MMedstar Health Research Institute·Phase 2·NCT00006669

GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Unknown status·FFrench Innovative Leukemia Organisation·Phase 2·NCT00893477·60 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003397·25 enrolled

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00073931·25 enrolled

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

Unknown status·FFrench Innovative Leukemia Organisation·Phase 2·NCT00896519·30 enrolled

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004197

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000689·18 enrolled

Melanoma17 trials

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

Completed·MMayo Clinic·Phase 1·NCT00568763·11 enrolled

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00003897·18 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Completed·UUniversity of Virginia·Phase 2·NCT00089206·7 enrolled

Show 14 more trials

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 1·NCT00118313

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089063·40 enrolled

Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Completed·—·Phase 2·NCT00014092

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT00017121·40 enrolled

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed·UUltimovacs ASA·Phase 2·NCT04382664·156 enrolled

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Completed·UUniversity of Southern California·Phase 2·NCT00003274·48 enrolled

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

Completed·JJohn P. Fruehauf·Phase 2·NCT00256282·52 enrolled

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Completed·CCraig L Slingluff, Jr·Phase 2·NCT00089193

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00031733·60 enrolled

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 3·NCT01826864

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Virginia·Phase 2·NCT00003222·40 enrolled

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00085579

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·N/A·NCT00006243·30 enrolled

Breast Cancer16 trials

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Completed·UUniversity of Washington·Phase 1·NCT02780401·32 enrolled

Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer

Completed·—·Phase 1·NCT00079157·28 enrolled

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052351

Show 13 more trials

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02636582·43 enrolled

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00048893·37 enrolled

Biological Therapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1/2·NCT00002780·60 enrolled

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00343109·38 enrolled

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Completed·MMayo Clinic·Phase 1·NCT00640861·45 enrolled

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Completed·PProvidence Cancer Center, Earle A. Chiles Research Institute·Phase 1·NCT00003184

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT01355393·50 enrolled

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Withdrawn·RRoger Williams Medical Center·Phase 1/2·NCT00022230

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00266110·17 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003972·280 enrolled

Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00179309·48 enrolled

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Unknown status·—·Phase 2·NCT04197687·480 enrolled

Neuroblastoma11 trials

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT04385277·41 enrolled

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00450307·32 enrolled

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00089258·74 enrolled

Show 8 more trials

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00040872

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT01334515·52 enrolled

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00005576·6 enrolled

Surgery in Treating Children With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003119·968 enrolled

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002560·40 enrolled

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01767194·73 enrolled

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Prostate Cancer8 trials

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

Completed·TThe Cleveland Clinic·Phase 2·NCT00400517·28 enrolled

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00108732·50 enrolled

Vaccine and Antibody Treatment of Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00113984·30 enrolled

Show 5 more trials

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

Completed·UUniversity of California, San Francisco·Phase 2·NCT00309894·49 enrolled

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00305669·24 enrolled

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

Completed·—·Phase 1/2·NCT00939510·32 enrolled

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02250014·19 enrolled

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020254

72 more indications

Multiple Myeloma8 trials

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Completed·MMayo Clinic·Phase 1/2·NCT00602706·76 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014508

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT02334865·18 enrolled

Show 5 more trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Unknown status·MMedical College of Wisconsin·Phase 2·NCT00003163·10 enrolled

Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019097

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Completed·UUniversity of Tennessee·Phase 2·NCT00003007

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Completed·TThe Cleveland Clinic·Phase 2·NCT00003490·30 enrolled

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005987·87 enrolled

Acute Myeloid Leukemia7 trials

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00630565·12 enrolled

Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00006240

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Unknown status·TThe Vaccine Company·Phase 3·NCT00454168·244 enrolled

Show 4 more trials

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00046930·449 enrolled

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00004217·55 enrolled

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00066794·69 enrolled

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00023777·71 enrolled

Metastatic Melanoma6 trials

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019383

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1·NCT00037037

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006385

Show 3 more trials

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00436930·200 enrolled

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019890

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Unknown status·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00002817·30 enrolled

Chronic Myelogenous Leukemia5 trials

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002598·30 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005948

Show 2 more trials

Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00466726·57 enrolled

Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003561·48 enrolled

Myelodysplastic Syndrome5 trials

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00425477·26 enrolled

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00462605·24 enrolled

Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003959·1 enrolled

Show 2 more trials

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00004918·69 enrolled

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Unknown status·TThe Vaccine Company·Phase 2·NCT00513578·30 enrolled

Rhabdomyosarcoma4 trials

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003958·702 enrolled

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025363·150 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Completed·CChildren's Oncology Group·Phase 2·NCT00003955·77 enrolled

Show 1 more trial

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002995·483 enrolled

Leukemia4 trials

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00005962

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01324063·160 enrolled

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Completed·—·Phase 2·NCT00047021·3 enrolled

Show 1 more trial

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00049517·657 enrolled

Advanced Cancer3 trials

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed·SSt. Vincent Medical Center - Los Angeles·Phase 2·NCT00002475·40 enrolled

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Completed·YYale University·Phase 1/2·NCT00002950·25 enrolled

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Unknown status·TThe Cleveland Clinic·Phase 1·NCT00004036·30 enrolled

Bone Marrow Transplantation3 trials

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003961

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002552·40 enrolled

Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00011934

Chronic Lymphocytic Leukemia3 trials

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 2·NCT00562328·33 enrolled

Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00265915

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00669318·41 enrolled

Non-Small Cell Lung Cancer3 trials

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00398138·22 enrolled

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 1·NCT00003002·60 enrolled

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005630

Effectiveness2 trials

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000850·108 enrolled

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000896·24 enrolled

Chemotherapy2 trials

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Terminated·GGynecologic Oncology Group·Phase 2·NCT00033644

Primary Peritoneal Cancer2 trials

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

Completed·UUniversity of Virginia·Phase 1·NCT00091273·9 enrolled

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Withdrawn·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT02470559

Kaposi's sarcoma2 trials

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000681·24 enrolled

A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000694·18 enrolled

Ovarian Cancer2 trials

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Completed·UUniversity of Washington·Phase 1·NCT00436254·66 enrolled

p53 Vaccine for Ovarian Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00001827·21 enrolled

Kidney Cancer2 trials

Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006483·27 enrolled

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Unknown status·HHope Cancer Institute, Inc.·Phase 2·NCT00003181·35 enrolled

Stem Cell Transplantation2 trials

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Completed·CCancer Treatment Centers of America·Phase 2·NCT00003408·40 enrolled

Metastatic Cancer2 trials

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00217373·33 enrolled

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00028496·48 enrolled

Metastatic Prostate Cancer2 trials

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00064129·42 enrolled

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00045227

HIV infection2 trials

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Completed· Novartis logo

Novartis·N/A·NCT00002007

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

Completed· Novartis logo

Novartis·Phase 1·NCT00002006

Glioblastoma Multiforme2 trials

Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·CCancer Research UK·Phase 1·NCT01222221·45 enrolled

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·JJohn Sampson·Phase 2·NCT00643097·40 enrolled

Soft Tissue Sarcoma2 trials

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Terminated·—·Phase 1·NCT00027911

Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery

Completed·MMayo Clinic·Phase 2·NCT00652860·39 enrolled

Colorectal Cancer2 trials

Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer

Completed·SSt. Luke's Medical Center·Phase 1/2·NCT00030342·60 enrolled

Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer

Unknown status·SSt. Luke's Medical Center·Phase 1·NCT00016042

Neutropenia2 trials

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Terminated·NNorthwestern University·Phase 1·NCT00005787·3 enrolled

A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine

Completed· Novartis logo

Novartis·N/A·NCT00002263

Mucositis2 trials

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00008398

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Completed·MMarilyn Dodd·Phase 3·NCT00293462·91 enrolled

Pancreatic Cancer2 trials

Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer

Completed·SSt. Vincent Medical Center - Los Angeles·Phase 2·NCT00002773

Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·RRoyal Liverpool University Hospital·Phase 3·NCT00425360·1,110 enrolled

Autoimmune Pulmonary Alveolar Proteinosis1 trial

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

Completed·—·Phase 1·NCT03006146·10 enrolled

Biological Therapy1 trial

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019084

Mantle Cell Lymphoma1 trial

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00006747·4 enrolled

Vaccine1 trial

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00009958·42 enrolled

Parkinson's Disease1 trial

Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease

Completed·UUniversity of Nebraska·Phase 1·NCT05677633·11 enrolled

Squamous Cell Carcinoma1 trial

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Completed·GGliknik Inc.·Phase 2·NCT02873819·80 enrolled

Intravenous1 trial

Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation

Completed·PPartner Therapeutics, Inc.·Phase 1·NCT05366283·42 enrolled

Adjuvant1 trial

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00381875·40 enrolled

Patients With Advanced Solid Tumors1 trial

Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors

Completed·SSirius Medicine·Phase 1/2·NCT00091052

Brain Tumor1 trial

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Completed·—·Phase 1·NCT00069940

Invasive Fungal Infection1 trial

Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection

Completed·MMedical Research Council·Phase 3·NCT00003315·200 enrolled

Lung Cancer1 trial

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00514215·8 enrolled

Metastatic Colorectal Cancer1 trial

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

Withdrawn·JJames Ahlgren·Phase 2·NCT00002664

Stage III Colon Cancer1 trial

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262808·50 enrolled

Hematologic Cancer1 trial

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Unknown status·BBenovus Bio, Inc.·Phase 1·NCT02240537·4 enrolled

Fallopian Tube Cancer1 trial

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Completed·UUniversity of Washington·Phase 2·NCT00466960·21 enrolled

Transitional Cell Carcinoma1 trial

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT00070070·6 enrolled

Metastatic Neuroendocrine Tumor1 trial

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03879694·19 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Trial1 trial

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Terminated·VVeeda Oncology·Phase 2·NCT00313482·35 enrolled

Cytomegalovirus (CMV)1 trial

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000989·50 enrolled

Osteosarcoma1 trial

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Completed·CChildren's Oncology Group·Phase 2·NCT00066365·49 enrolled

Oligodendroglioma1 trial

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004024·60 enrolled

Urothelial Cancer1 trial

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

Terminated·UUniversity of Kentucky·Phase 3·NCT00237575·100 enrolled

Retinitis1 trial

Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis

Completed·SSchering-Plough·Phase 3·NCT00002070

COVID-191 trial

Study of Sargramostim in Patients With COVID-19

Completed·PPartner Therapeutics, Inc.·Phase 2·NCT04411680·123 enrolled

Stage III1 trial

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Completed·UUniversity of Washington·Phase 1·NCT00005023

Metastatic Solid Tumors1 trial

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019331

Immune1 trial

Inhaled GM-CSF Therapy of Autoimmune PAP

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT00901511·18 enrolled

Patients With Solid Tumors1 trial

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

Withdrawn·PPartner Therapeutics, Inc.·Phase 2·NCT05284214

Bone Marrow Transplant1 trial

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Completed·TTemple University·Phase 2·NCT00002809·10 enrolled

Head and Neck Cancer1 trial

Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer

Completed·NNYU Langone Health·N/A·NCT00899821

Pulmonary Alveolar Proteinosis1 trial

Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan

Completed·NNiigata University Medical & Dental Hospital·Phase 2·NCT02835742·78 enrolled

Interleukin1 trial

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Completed·GGeorgetown University·Phase 2·NCT00003125·24 enrolled

Infection1 trial

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

Completed· Novartis logo

Novartis·Phase 1·NCT00002008

Completed·RRobin Kate Kelley·Phase 2·NCT02703714·42 enrolled

Primary Systemic Amyloidosis1 trial

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007995·75 enrolled

Maintenance Treatment1 trial

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01700673·25 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00242996·44 enrolled

Hematological Malignancy1 trial

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Completed·VVirginia Commonwealth University·Phase 2·NCT02593123·31 enrolled

Stem Cell Transplant1 trial

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00448201·71 enrolled

Malignant Glioma1 trial

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008008·40 enrolled

Unspecified1 trial

MIBG With Dinutuximab +/- Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT03332667·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 306 trial records for sargramostim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sargramostim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sargramostim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Granulocyte-Macrophage Colony-Stimulating Factor Receptor Agonist[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Leukine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Lymphoma20 trials

Melanoma17 trials

Breast Cancer16 trials

Neuroblastoma11 trials

Prostate Cancer8 trials

Multiple Myeloma8 trials

Acute Myeloid Leukemia7 trials

Metastatic Melanoma6 trials

Chronic Myelogenous Leukemia5 trials

Myelodysplastic Syndrome5 trials

Rhabdomyosarcoma4 trials

Leukemia4 trials

Advanced Cancer3 trials

Bone Marrow Transplantation3 trials

Chronic Lymphocytic Leukemia3 trials

Non-Small Cell Lung Cancer3 trials

Effectiveness2 trials

Chemotherapy2 trials

Primary Peritoneal Cancer2 trials

Kaposi's sarcoma2 trials

Ovarian Cancer2 trials

Kidney Cancer2 trials

Stem Cell Transplantation2 trials

Metastatic Cancer2 trials

Metastatic Prostate Cancer2 trials

HIV infection2 trials

Glioblastoma Multiforme2 trials

Soft Tissue Sarcoma2 trials

Colorectal Cancer2 trials

Neutropenia2 trials

Mucositis2 trials

Pancreatic Cancer2 trials

Autoimmune Pulmonary Alveolar Proteinosis1 trial

Biological Therapy1 trial

Mantle Cell Lymphoma1 trial

Vaccine1 trial

Parkinson's Disease1 trial

Squamous Cell Carcinoma1 trial

Intravenous1 trial

Adjuvant1 trial

Patients With Advanced Solid Tumors1 trial

Brain Tumor1 trial

Invasive Fungal Infection1 trial

Lung Cancer1 trial

Metastatic Colorectal Cancer1 trial

Stage III Colon Cancer1 trial

Hematologic Cancer1 trial

Fallopian Tube Cancer1 trial

Transitional Cell Carcinoma1 trial

Metastatic Neuroendocrine Tumor1 trial

Malignant Solid Tumors1 trial

Trial1 trial

Cytomegalovirus (CMV)1 trial

Osteosarcoma1 trial

Oligodendroglioma1 trial

Urothelial Cancer1 trial

Retinitis1 trial

COVID-191 trial

Stage III1 trial

Metastatic Solid Tumors1 trial

Immune1 trial

Patients With Solid Tumors1 trial

Bone Marrow Transplant1 trial

Head and Neck Cancer1 trial

Pulmonary Alveolar Proteinosis1 trial

Interleukin1 trial

Infection1 trial

Gastrointestinal1 trial

Brain Cancer1 trial

Biliary Cancer1 trial

Primary Systemic Amyloidosis1 trial

Maintenance Treatment1 trial

Diffuse Large B-Cell Lymphoma1 trial

Hematological Malignancy1 trial